Explanation:

RTS,S/AS01, trade name Mosquirix, is an injectable vaccine targeting P. falciparum, the most prevalent malaria strain in Africa. It is the first and only vaccine to show partial protection in young children.

• It was developed by British drugmaker GlaxoSmithKline in 1987.
• The active substance in Mosquirix is made up of proteins found on the surface of the Plasmodium falciparum parasites (PFP).
• RTS,S aims to trigger the immune system to defend against the first stages of malaria when the PFP enters the human host’s bloodstream through a mosquito bite and infects liver cells.
• It also helps protect against infection of the liver with the Hepatitis B virus.
• The vaccine's effectiveness at preventing severe cases of malaria in children is only around 30%, but it is the only approved vaccine.
• The European Union's drugs regulator approved it in 2015, saying its benefits outweighed the risks.
• Its side effects are rare, but sometimes include a fever that may result in temporary convulsions.

Hence both statements 1&2 are correct.